.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
Remedi’s category mix in May 2026 concentrated further into Concentrates at 88.96% share, up alongside a 22.49% year-over-year sales increase even as month-over-month dipped 2.34%; in contrast, Tincture & Sublingual held 9.86% share with a 54.43% year-over-year decline and a 6.99% month-over-month slide. Capsules shrank to 1.19% share with an 84.54% year-over-year drop and a 28.06% month-over-month decline, while the brand’s overall average price fell 11.15% year-over-year to $21.30 and total brand sales were down 1.89% year-over-year. The pattern implies Remedi is consolidating around a single growth engine while trimming or losing traction in smaller formats, creating higher dependency risk despite Concentrates growth.
Positioning now hinges on Concentrates performance where Remedi ranked 20th in Illinois for Concentrates, with Concentrates momentum up 22.49% year-over-year but softening 2.34% month-over-month as prices declined 11.15% year-over-year. The dual contraction in Tincture & Sublingual (down 54.43% year-over-year and 6.99% month-over-month) and Capsules (down 84.54% year-over-year and 28.06% month-over-month) signals a narrower demand footprint, implying the brand’s near-term positioning is tied to defending rank in Concentrates while price-led tactics risk compressing mix breadth.
Competitive Landscape
Remedi ranks #20 in Illinois Concentrates in May 2026, improving 3 positions from #23 year over year, but down 1 spot from #19 at its November 2025 peak; over the last quarter it slipped from #22 to #20, a 2-rank gain that contrasts with IC Collective moving from #7 to #3 and with Superflux rising from #8 to #4 despite a -7.49% year-over-year sales change. Competitive pressure is mixed at the top as Aeriz holds #1 with a -17.34% YoY sales decline while RYTHM stays #2 with +20.13% YoY growth, indicating that rank mobility is not strictly tied to growth rates; the pattern implies Remedi’s modest rank climb is driven by relative slippage among incumbents rather than outsized share capture, signaling a fragile hold on the top-20 unless conversion widens beyond a 1–3 rank swing.
Notable Products
Hybrid Relief RSO Syringe (0.5g) posted the standout move in May 2026 with an 80.6% month-over-month surge to rank 4, while OG Kush Breath RSO Syringe (1g) fell 30.5% and Indica Rest RSO Dropper (0.5g) declined 12.5%, reshuffling mid-pack momentum. At the top, Indica Rest RSO Syringe (0.5g) rose 25.8% to rank 1 as Indica Relief RSO Syringe (0.5g) slipped 5.4% at rank 2, concentrating the lead around Rest and Relief formats. With eight of the top ten positioned in Concentrates and only two Tincture & Sublingual entries holding ranks 5 and 6 with +0.3% and -8.1% respectively, the assortment is tilting toward RSO syringes over tinctures. The pattern implies Remedi is consolidating share in RSO-led Concentrates while ceding velocity in select 1g strains, pointing to a focus on 0.5g functional SKUs that can scale volume over flavor-led variants.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
